Tubular response to hormones is blunted in weanling rats.
The renal responses to atrial natriuretic peptide (ANP), parathyroid hormone (PTH) and arginine vasopressin (AVP) were studied in anaesthetized weanling and adult rats with clearance methods. In rats receiving PTH, thyroparathyroidectomy (TPTX) was performed prior to the study. The results showed that GRF remained unchanged in both age groups during infusion with ANP, AVP and PTH after TPTX as well as with TPTX alone. During ANP infusion, the urine flow rate increased from 0.01 +/- 0.002 to 0.029 +/- 0.004 ml (100 g body wt)-1 min-1 (P less than 0.001) and the fractional sodium excretion increased from 0.48 +/- 0.1 to 3.0 +/- 0.4% (P less than 0.001) in the adult rats; no significant changes were observed in the weanling rats. Phosphate excretion was not influenced by ANP in either age group. After TPTX, both net and fractional phosphate excretion decreased in both age groups. During PTH infusion in TPTX rats, both net and fractional phosphate excretions increased significantly in the adult rats but were unchanged in the weanling rats. In rats of the same age, the renal concentrating capacity and urinary excretion of prostaglandin E2 (PGE2) were determined after dehydration. The renal concentrating capacity was lower, and the renal excretion of PGE2 was higher, in the weanling than in the adult rats. Furthermore, the concentrating mechanism seems not to be influenced by indomethacin treatment in either age group. It is concluded that the tubular responses to ANP and PTH are blunted in the immature kidney and that the renal excretion of PGE2 is not an important factor in the regulation of the concentrating capacity in the weanling rat.
Karlén
J
J
Department of Pediatrics, St Göran's Children's Hospital, Karolinska Institute, Stockholm, Sweden.
Rane
S
S
Aperia
A
A
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D006706:Homeostasis / Q000187:drug effects / Q000502:physiology; D007213:Indomethacin / Q000494:pharmacology; D007262:Infusions, Intravenous; D007678:Kidney Glomerulus / Q000502:physiology*; D007684:Kidney Tubules / Q000502:physiology*; D008297:Male; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D011453:Prostaglandins / Q000494:pharmacology / Q000652:urine; D051381:Rats; D011919:Rats, Inbred Strains; D014556:Urine / Q000032:analysis; D014667:Vasopressins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D014882:Water-Electrolyte Balance / Q000187:drug effects / Q000502:physiology; D014886:Weaning
D010281:Parathyroid Hormone; D011453:Prostaglandins; D014667:Vasopressins; D009320:Atrial Natriuretic Factor; D007213:Indomethacin